SHOCKING DISCOVERY: Israeli AI Company Quris-AI Teams up with Merck KGaA to Revolutionize Drug Development!
In a groundbreaking collaboration, Israeli pharmaceutical AI developer Quris-AI and respected scientific firm Merck KGaA have joined forces to bring us the future of drug development. This dynamic duo has conducted a preclinical investigation that compares Quris-AI’s cutting-edge medication toxicity prediction capabilities with traditional methods.
Merck plans to tap into Quris-AI’s expertise in assessing liver toxicity risks in potential medication candidates. And if all goes well, they have the option to secure an exclusive five-year license in the disease domain. We’re talking BIG bucks, with estimates suggesting that the financial details of this deal could reach tens of millions!
Quris-AI is no stranger to success, securing an impressive $37 million in seed funding by December 2022. Their list of investors reads like a who’s who of the business world, with big names like SoftBank Vision Fund 2, GlenRock Capital, and Richter Group jumping on board. These investors have contributed a massive $9 million in seed capital, showing that this collaboration has serious potential.
Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for Merck KGaA’s Healthcare business sector, is thrilled about this ongoing partnership. He sees immense potential in Quris-AI’s BioAI platform and believes it could revolutionize drug development and testing programs. The goal? An AI-enabled IND process that cuts down on animal testing, saving time and resources.
But what about the results? Well, Quris-AI’s technology has already shown an impressive ability to accurately predict which medications might cause liver harm. With 29 granted and pending patents, their BioAI platform is a testament to their dedication to accelerating drug development, reducing costs, and eliminating risky animal testing.
Dr. Isaac Bentwich, CEO of Quris-AI, is passionate about the role of technology in medicine development. He knows that accurately forecasting the safety of innovative medications can speed up the path to market, saving lives and cutting costs along the way. Dr. Bentwich is excited to continue collaborating with Merck KGaA in advancing pharmaceutical research.
This partnership between Quris-AI and Merck KGaA is a game-changer. It’s a step towards more efficient and ethical drug development, benefiting both the industry and patients in need of safe and effective medications. Can you imagine a future where AI leads the way in drug development? We want to hear your thoughts! Leave a comment and let us know what you think about this incredible partnership.
IntelliPrompt curated this article: Read the full story at the original source by clicking here